Half-year transcripts of 10 multinational pharmaceutical companies: led by Johnson & Johnson, Roche's new drugs are in force, Pfizer's new crown vaccine sold 11.3 billion US dollars, Novartis, BMS, Gilead...
August 02, 2021
Since July, according to incomplete statistics from Yaozhi.com, as of July 30, 10 companies including Johnson & Johnson, Pfizer, Roche, Novartis, and BMS have successively announced mid-year reports for the first half of 2021. Among them, Johnson & Johnson Pharmaceuticals ranked second with US$45.633 billion in revenue for multinational pharmaceutical companies in the first half of 2021, followed by Roche Pharmaceuticals with US$33.877 billion, ranking second; Pfizer ranked third with US$33.5 billion. In terms of growth rate, in the first half of 2021, except for Bojian, despite the impact of the new crown epidemic, all major companies have achieved different levels of growth. Among them, Pfizer has the fastest growth rate, with revenue reaching 335 in the first half of 2021. Billion US dollars, an increase of 68% year-on-year. Followed by AstraZeneca, which increased by 23% year-on-year; Gilead Sciences and Johnson & Johnson increased by 18.23% and 17% respectively.
Revenue overview of 10 multinational pharmaceutical companies
Johnson & Johnson's sales of US$45.633 billion, innovative drugs contribute more than half
On July 21, Johnson & Johnson announced the first half of 2021 financial report. The financial report data showed that the total revenue in the first half of the year was 45.633 billion US dollars, a year-on-year increase of 16.9%. Among the three major business segments (pharmaceuticals, medical devices and consumer health); innovative drugs are still the main source of revenue, with revenue of 24.798 billion US dollars in the first half of the year, a year-on-year increase of 13.3%; accounting for 54.24% of total revenue. Anti-inflammatory drug Stelara (usnumab), CD38-targeted anti-AIDS drug Darzalex (daretuzumab), Imbruvica (ibrutinib), psoriasis drug Tremfya (guselkumab), prostate cancer drug Erleada (Apatamide) has become its main driving force for revenue growth. Among them, the sales of Usnuzumab were up to US$4.422 billion; followed by daratumumab and Ibritinib, with sales of US$2.798 billion and US$2.241 billion, respectively. In addition, the fastest growing is Erleada (apatamide), with sales of US$563 million in the first half of 2021, an increase of more than 80%. It is also worth mentioning that Johnson & Johnson's COVID-19 vaccine has provided new growth potential for it, achieving a revenue of US$264 million in the first half of the year; however, due to factors such as safety and mutation of the diseased strain, the market has grown slowly.
Roche’s "Troika" sales drop by 40%, new drugs boost performance
On July 22, Roche released a semi-annual report. The financial report data showed that the total global revenue of Roche Pharmaceuticals in the first half of the year was 30.713 billion Swiss francs (US$33.877 billion), an increase of 8% year-on-year. Like Johnson & Johnson, the pharmaceutical sector's revenue is its business. The main source of revenue accounted for 70.56%, reaching 21.671 billion Swiss francs. However, due to the impact of biosimilars and the new crown epidemic, the pharmaceutical business revenue fell -3% year-on-year; rituximab, bevacizumab and The sales of trastuzumab "troika" in the first half of the year all fell by about 40%.
On the other hand, the new drugs approved in recent years are constantly becoming a new driving force for performance growth. The CD20 monoclonal antibody that went on the market in 2017-Ocrevus has the largest sales in the first half of 2021, reaching 2.438 billion Swiss francs; dual-specific factor IXa and The factor X targeted antibody Hemlibra has the fastest growth, with a year-on-year increase of 45%, reaching 1.393 billion Swiss francs.
Pfizer's revenue increased by 68%, mRNA new crown vaccine sold for $11.3 billion in half a year
On July 28, Pfizer announced its financial report for the second quarter of 2021; total revenue for the first half of the year was US$33.5 billion, a year-on-year increase of 68%. Innovative products Eliquis (apixaban), Ibrance (pibecili), Xtandi (enzalutamide) and biosimilar drugs are the main factors for its growth. However, the sales revenue of the heavyweight Ibrance (pibecili) continued to slow down. It is particularly worth noting that the mRNA new crown vaccine has become a strong booster for Pfizer's performance growth in the first half of the year, with sales reaching 11.3 billion US dollars! It accounts for 33.73% of the entire revenue, making it Pfizer's highest-selling product in the first half of the year. It is also worth mentioning that Pfizer Pharmaceuticals introduced the latest progress of 8 potential "first-in-class" research and development projects in the second quarter earnings report during the conference call, including the mRNA new crown vaccine jointly developed by Pfizer and BioNTech as an enhanced vaccination vaccine The performance indicates that 6 months after the second dose of the BNT162b2 vaccine, the third dose of the booster vaccine showed the same safety characteristics as before. For wild-type viruses, the neutralizing antibody titer after the third dose of vaccine is 5-8 times higher than that after the second dose of vaccine. With the global spread of the new crown epidemic and the continuous mutation of diseased strains, the third booster shot has become inevitable. In this way, Pfizer Pharmaceuticals' new crown vaccine may continue to increase its volume, which will further contribute to its performance.
Novartis revenue of $25.4 billion, gene therapy sales up 69%
On July 21, Novartis announced the 2021 semi-annual report. In the first half of the year, revenue was US$25.367 billion, a year-on-year increase of 7%, and net profit was US$4.954 billion, a year-on-year increase of 23%. In the two main business lines of innovative drugs and generic drugs, innovative business is the main source of performance. In the first half of the year, the net sales of innovative drugs were US$20.7 billion, a year-on-year increase of 9%. The blockbuster Cosentyx of the Department of Rheumatology and Immunology has achieved revenue of US$2.228 billion in the first half of 2021, making it the drug with the highest sales in the first half of 2021; sales of Zolgensma, a gene therapy for spinal muscular atrophy, in the first half of 2021 The growth rate was the fastest, with a year-on-year growth of nearly 70% ($634 million); secondly, sacubatril and valsartan also performed well in the first half of the year, achieving revenue of US$1.675 billion, 46% year-on-year.
BMS "O medicine" vitality recovery, innovative drugs contribute more than 90% of the performance
On July 28, Bristol-Myers Squibb (BMS) announced its 2021Q2 results, with total revenue of US$22.776 billion in the first half of the year, a year-on-year increase of 9%. The revenue of heavy brand drugs in the first half of the year contributed more than 90% of the company's revenue. Among them, in the field of immunology, the sales of immunomodulator Revlimid (lenalidomide) was the highest at US$6.146 billion; followed by the blockbuster anticoagulant drug Eliquis, which achieved revenue of US$5.678 billion, an increase of 18% year-on-year; Point inhibitor Yervoy's revenue in the first half of the year was close to US$1 billion, an increase of 26% year-on-year, making it the fastest-growing drug this year.
In addition, "O drug" Opdivo experienced a decline in performance in 2020 due to the impact of the epidemic, but it gradually "recovered" into 2021, with revenue in the first half of the year exceeding US$3.6 billion; newly launched products in recent years have also continued to exert strength, Reblozyl, Zeposia And Onureg's performance in the first half of the year has also risen, and it is expected to grow into a blockbuster product supporting BMS revenue in the future. In terms of research and development, BMS is also making continuous efforts. The research and development expenditure of BMS in the first half of the year was US$5.5 billion, and the research and development expenditure in the second quarter was US$3.271 billion.
Merck's revenue of $22 billion K medicine remains strong
On July 29, Merck announced its financial report for the second quarter of 2021. The total revenue in the first half of the year was US$22.029 billion, a year-on-year increase of 12%; of which, the pharmaceutical business contributed US$19.218 billion in the first half of the year, a year-on-year increase of 12%. Due to the impact of the epidemic in 2020, the performance of many models has slowed down and gradually recovered in 2021. Among them, the cumulative revenue of Gardasil 9/Gardasil and Bridion in the first half of the year was 2.151 billion U.S. dollars (+23%); 727 million U.S. dollars (+39) %). In addition, K drug sales revenue was US$8.078 billion, an increase of 23% over the same period last year. At the same time, we are constantly developing and introducing COVID-19 treatment products.
Sanofi's revenue of 17.3 billion euros, Duplizumab performs well
On July 29, Sanofi announced the 2021 half-year financial report data. The revenue totaled 17.3 billion euros. The pharmaceutical business and vaccine business revenues were 13.4 billion euros (+1.4%) and 1.94 billion euros (+5.5%), respectively. Among them, Dupixent, a blockbuster drug for the treatment of atopic dermatitis and asthma, performed well, with sales revenue of 2.29 billion euros in the first half of the year. Dupixent is currently available in 44 countries and is expected to be launched in 54 other countries this year. In China, Dupixent was approved in June this year, and it is expected that more than 150,000 patients will be eligible for treatment. According to EvaluatePharma's forecast report, Dupixent will reach 9.386 billion U.S. dollars in sales in 2026, becoming the world's best-selling anti-inflammatory drug. In addition, the PD-1 monoclonal antibody Libtayo (cemiplimab) and the CD38 monoclonal antibody Sarclisa (isatuximab) have a small sales base, but they are still in the stage of performance growth.
AstraZeneca's revenue in the first half of the year was 15.54 billion U.S. dollars, and the new crown vaccine sold 1.136 billion U.S. dollars
On July 29, AstraZeneca released its 2021 semi-annual report. The revenue for the first half of the year was US$15.54 billion, an increase of 23% year-on-year; it benefited from the contribution of the acquisition of Alexion Pharmaceuticals and the sales growth of anti-tumor products. According to the financial report, the anti-tumor business's anti-tumor segment revenue was US$ 6.36 billion, a year-on-year increase of 19%; among them, the third-generation EGFR targeted drug Tagrisso (Teresa) sold best, with revenue of US$2.454 billion in the first half of the year, a year-on-year increase. 22%; In addition, Farxiga (Daggliflozin) has the fastest growth, with a year-on-year growth of 60%. In addition, despite the impact of the thrombotic event, the new crown vaccine sold 1.136 billion US dollars in the first half of the year. In addition, high investment in mergers and acquisitions and research and development to supplement pipelines and new products in the first half of the year, AstraZeneca R & D expenses reached 3.542 billion US dollars in the first half of the year, an increase of more than 20%. Used for R&D investment in its new crown vaccine, drugs and anti-tumor pipeline.
Gilead Sciences turns losses into profits, and demand for remdesivir grows
In July, Lead Scientific released the company's 2021 fiscal year interim report. Operating income was US$12.64 billion, an increase of 18.23% year-on-year, and net profit was US$3.227 billion; the main reasons were Veklury, Biktarv and hepatitis C virus (HCV). Product demand increases.
According to the financial report, Gilead Sciences has raised its 2021 full-year performance guidance. It is expected that the annual product sales of 2021 will be between 24.4 billion and 25 billion US dollars. The solid performance in the first half of the year and the latest expectations for the second half of 2021. The company has also updated other performance guidelines. It is expected that the product sales (excluding Veklury) for the full year of 2021 will be between 21.7 billion and 21.9 billion US dollars, compared with 21.7 billion-22.1 billion US dollars; Veklury sales will be 2.7 billion to 21.9 billion US dollars. 3.1 billion U.S. dollars, from 2 billion to 3 billion U.S. dollars before.
Bojian's net profit fell by more than 50%, Aduhelm's half-month sales income of 1.6 million US dollars
On July 23, Bojian announced its 2021 semi-annual report. In the first half of the year, its operating income was US$5.469 billion, a year-on-year decline of 24.21%, of which product revenue was US$4.448 billion, a year-on-year decline of -21.97%; net profit was US$1.430 billion, a year-on-year decrease of 52.31%. Due to fierce competition from generic drugs, Tecfidera sold only US$967 million in the first half of the year, a year-on-year decline of 57.60%; however, sales of Spinraza (Nosina Sodium) and Tysabri (natalizumab) increased slightly, but it is difficult to reduce Tecfidera’s decline. . It is worth noting that Biogen's new Alzheimer's disease drug Aduhelm (aducanumab), which was approved by the FDA in June of this year, has been on the market for only half a month, and has contributed $1.6 million in revenue to the company.
